Global Live Attenuated Vaccines

Live Attenuated Vaccines Comprehensive Study by Type (Bacterial, Viral), Application (Hospitals, Clinics, Research Institutes, Others), (), End Use (Geriatrics, Adults, Adolescents, Child), Vaccines (Measles, mumps, rubella (MMR combined vaccine), Rotavirus, Smallpox, Chickenpox, Yellow fever) Players and Region - Global Market Outlook to 2030

Live Attenuated Vaccines Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Live Attenuated Vaccines Market Scope
Live Attenuated Vaccines market is expected to grow in the future due to the rising prevalence of infectious diseases and growing government funding for vaccine programs. A live attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it live. They are antigenic substances composed of a viable pathogen, such as a virus or bacterium. The pathogen is altered so that it is less virulent or attenuated. The high growth of live attenuated vaccine production in emerging markets is expected to offer lucrative opportunities in the near future.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledGlaxoSmithKline Plc. (United Kingdom), Merck & Co. (United States), Novartis International AG (Switzerland), Pfizer, Inc. (United States), Astellas Pharma Inc. (Japan), Johnson & Johnson (United States), CSL Limited (Australia), Emergent BioSolution, Inc. (United States) and MedImmune, LLC (United States)
CAGR6.7%


the global live attenuated vaccines market is fragmented and the leading pharmaceutical companies are working on their research and development team to clear all the clinical trials and get approval from the FDA to launch its vaccines. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Live Attenuated Vaccines market throughout the predicted period.

GlaxoSmithKline Plc. (United Kingdom), Merck & Co. (United States), Novartis International AG (Switzerland), Pfizer, Inc. (United States), Astellas Pharma Inc. (Japan), Johnson & Johnson (United States), CSL Limited (Australia), Emergent BioSolution, Inc. (United States) and MedImmune, LLC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sanofi (France) and Serum Institute Of India Pvt. Ltd. (India).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Live Attenuated Vaccines market by Type , by Application (Hospitals, Clinics, Research Institutes and Others) and Region with country level break-up.

On the basis of geography, the market of Live Attenuated Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In MAY 17, 2023, Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, and IAVI, an international nonprofit research organization focused on developing vaccines and antibodies against infectious and neglected diseases, today announced the signing of an agreement for end-to-end development of the tuberculosis (TB) vaccine candidate MTBVAC.
In May 2023, he U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.


Influencing Trend:
Rising Clinical Trial for New Vaccines and Technological Progress in Vaccine Administration

Market Growth Drivers:
Rising Awareness of Vaccination Worldwide and Increasing Government Initiative and Providing Fundings for Vaccine Programs

Challenges:
Longer Timelines Required for Vaccine Production

Restraints:
High Costs Associated with the Development of Vaccines

Opportunities:
Improving Health Care Infrasture in Developing Countries and High Growth Prospects in Emerging Markets

Key Target Audience
Live Attenuated Vaccines Manufacturers, Live Attenuated Vaccines Suppliers, Raw Material Suppliers, Research and Development Organization, Potential Investors and Government Agencies

Report Objectives / Segmentation Covered

By Type
  • Bacterial
  • Viral
By Application
  • Hospitals
  • Clinics
  • Research Institutes
  • Others
By End Use
  • Geriatrics
  • Adults
  • Adolescents
  • Child

By Vaccines
  • Measles, mumps, rubella (MMR combined vaccine)
  • Rotavirus
  • Smallpox
  • Chickenpox
  • Yellow fever

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness of Vaccination Worldwide
      • 3.2.2. Increasing Government Initiative and Providing Fundings for Vaccine Programs
    • 3.3. Market Challenges
      • 3.3.1. Longer Timelines Required for Vaccine Production
    • 3.4. Market Trends
      • 3.4.1. Rising Clinical Trial for New Vaccines
      • 3.4.2. Technological Progress in Vaccine Administration
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Live Attenuated Vaccines, by Type, Application, , End Use, Vaccines and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Live Attenuated Vaccines (Value)
      • 5.2.1. Global Live Attenuated Vaccines by: Type (Value)
        • 5.2.1.1. Bacterial
        • 5.2.1.2. Viral
      • 5.2.2. Global Live Attenuated Vaccines by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Research Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Live Attenuated Vaccines by: End Use (Value)
        • 5.2.3.1. Geriatrics
        • 5.2.3.2. Adults
        • 5.2.3.3. Adolescents
        • 5.2.3.4. Child
      • 5.2.4. Global Live Attenuated Vaccines by: Vaccines (Value)
        • 5.2.4.1. Measles, mumps, rubella (MMR combined vaccine)
        • 5.2.4.2. Rotavirus
        • 5.2.4.3. Smallpox
        • 5.2.4.4. Chickenpox
        • 5.2.4.5. Yellow fever
      • 5.2.5. Global Live Attenuated Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Live Attenuated Vaccines (Volume)
      • 5.3.1. Global Live Attenuated Vaccines by: Type (Volume)
        • 5.3.1.1. Bacterial
        • 5.3.1.2. Viral
      • 5.3.2. Global Live Attenuated Vaccines by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Research Institutes
        • 5.3.2.4. Others
      • 5.3.3. Global Live Attenuated Vaccines by: End Use (Volume)
        • 5.3.3.1. Geriatrics
        • 5.3.3.2. Adults
        • 5.3.3.3. Adolescents
        • 5.3.3.4. Child
      • 5.3.4. Global Live Attenuated Vaccines by: Vaccines (Volume)
        • 5.3.4.1. Measles, mumps, rubella (MMR combined vaccine)
        • 5.3.4.2. Rotavirus
        • 5.3.4.3. Smallpox
        • 5.3.4.4. Chickenpox
        • 5.3.4.5. Yellow fever
      • 5.3.5. Global Live Attenuated Vaccines Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Live Attenuated Vaccines (Price)
      • 5.4.1. Global Live Attenuated Vaccines by: Type (Price)
  • 6. Live Attenuated Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CSL Limited (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Emergent BioSolution, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. MedImmune, LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Live Attenuated Vaccines Sale, by Type, Application, , End Use, Vaccines and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Live Attenuated Vaccines (Value)
      • 7.2.1. Global Live Attenuated Vaccines by: Type (Value)
        • 7.2.1.1. Bacterial
        • 7.2.1.2. Viral
      • 7.2.2. Global Live Attenuated Vaccines by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Research Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Live Attenuated Vaccines by: End Use (Value)
        • 7.2.3.1. Geriatrics
        • 7.2.3.2. Adults
        • 7.2.3.3. Adolescents
        • 7.2.3.4. Child
      • 7.2.4. Global Live Attenuated Vaccines by: Vaccines (Value)
        • 7.2.4.1. Measles, mumps, rubella (MMR combined vaccine)
        • 7.2.4.2. Rotavirus
        • 7.2.4.3. Smallpox
        • 7.2.4.4. Chickenpox
        • 7.2.4.5. Yellow fever
      • 7.2.5. Global Live Attenuated Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Live Attenuated Vaccines (Volume)
      • 7.3.1. Global Live Attenuated Vaccines by: Type (Volume)
        • 7.3.1.1. Bacterial
        • 7.3.1.2. Viral
      • 7.3.2. Global Live Attenuated Vaccines by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Research Institutes
        • 7.3.2.4. Others
      • 7.3.3. Global Live Attenuated Vaccines by: End Use (Volume)
        • 7.3.3.1. Geriatrics
        • 7.3.3.2. Adults
        • 7.3.3.3. Adolescents
        • 7.3.3.4. Child
      • 7.3.4. Global Live Attenuated Vaccines by: Vaccines (Volume)
        • 7.3.4.1. Measles, mumps, rubella (MMR combined vaccine)
        • 7.3.4.2. Rotavirus
        • 7.3.4.3. Smallpox
        • 7.3.4.4. Chickenpox
        • 7.3.4.5. Yellow fever
      • 7.3.5. Global Live Attenuated Vaccines Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Live Attenuated Vaccines (Price)
      • 7.4.1. Global Live Attenuated Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Live Attenuated Vaccines: by Type(USD Million)
  • Table 2. Live Attenuated Vaccines Bacterial , by Region USD Million (2018-2023)
  • Table 3. Live Attenuated Vaccines Viral , by Region USD Million (2018-2023)
  • Table 4. Live Attenuated Vaccines: by Application(USD Million)
  • Table 5. Live Attenuated Vaccines Hospitals , by Region USD Million (2018-2023)
  • Table 6. Live Attenuated Vaccines Clinics , by Region USD Million (2018-2023)
  • Table 7. Live Attenuated Vaccines Research Institutes , by Region USD Million (2018-2023)
  • Table 8. Live Attenuated Vaccines Others , by Region USD Million (2018-2023)
  • Table 9. Live Attenuated Vaccines: by End Use(USD Million)
  • Table 10. Live Attenuated Vaccines Geriatrics , by Region USD Million (2018-2023)
  • Table 11. Live Attenuated Vaccines Adults , by Region USD Million (2018-2023)
  • Table 12. Live Attenuated Vaccines Adolescents , by Region USD Million (2018-2023)
  • Table 13. Live Attenuated Vaccines Child , by Region USD Million (2018-2023)
  • Table 14. Live Attenuated Vaccines: by Vaccines(USD Million)
  • Table 15. Live Attenuated Vaccines Measles, mumps, rubella (MMR combined vaccine) , by Region USD Million (2018-2023)
  • Table 16. Live Attenuated Vaccines Rotavirus , by Region USD Million (2018-2023)
  • Table 17. Live Attenuated Vaccines Smallpox , by Region USD Million (2018-2023)
  • Table 18. Live Attenuated Vaccines Chickenpox , by Region USD Million (2018-2023)
  • Table 19. Live Attenuated Vaccines Yellow fever , by Region USD Million (2018-2023)
  • Table 20. South America Live Attenuated Vaccines, by Country USD Million (2018-2023)
  • Table 21. South America Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 22. South America Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 23. South America Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 24. South America Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 25. Brazil Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 26. Brazil Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 27. Brazil Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 28. Brazil Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 29. Argentina Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 30. Argentina Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 31. Argentina Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 32. Argentina Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 33. Rest of South America Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 34. Rest of South America Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 35. Rest of South America Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 36. Rest of South America Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 37. Asia Pacific Live Attenuated Vaccines, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 39. Asia Pacific Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 40. Asia Pacific Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 41. Asia Pacific Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 42. China Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 43. China Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 44. China Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 45. China Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 46. Japan Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 47. Japan Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 48. Japan Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 49. Japan Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 50. India Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 51. India Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 52. India Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 53. India Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 54. South Korea Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 55. South Korea Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 56. South Korea Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 57. South Korea Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 58. Taiwan Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 59. Taiwan Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 60. Taiwan Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 61. Taiwan Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 62. Australia Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 63. Australia Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 64. Australia Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 65. Australia Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 70. Europe Live Attenuated Vaccines, by Country USD Million (2018-2023)
  • Table 71. Europe Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 72. Europe Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 73. Europe Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 74. Europe Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 75. Germany Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 76. Germany Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 77. Germany Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 78. Germany Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 79. France Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 80. France Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 81. France Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 82. France Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 83. Italy Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 84. Italy Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 85. Italy Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 86. Italy Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 87. United Kingdom Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 88. United Kingdom Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 89. United Kingdom Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 90. United Kingdom Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 91. Netherlands Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 92. Netherlands Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 93. Netherlands Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 94. Netherlands Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 95. Rest of Europe Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 96. Rest of Europe Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 97. Rest of Europe Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 98. Rest of Europe Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 99. MEA Live Attenuated Vaccines, by Country USD Million (2018-2023)
  • Table 100. MEA Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 101. MEA Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 102. MEA Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 103. MEA Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 104. Middle East Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 105. Middle East Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 106. Middle East Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 107. Middle East Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 108. Africa Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 109. Africa Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 110. Africa Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 111. Africa Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 112. North America Live Attenuated Vaccines, by Country USD Million (2018-2023)
  • Table 113. North America Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 114. North America Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 115. North America Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 116. North America Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 117. United States Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 118. United States Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 119. United States Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 120. United States Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 121. Canada Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 122. Canada Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 123. Canada Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 124. Canada Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 125. Mexico Live Attenuated Vaccines, by Type USD Million (2018-2023)
  • Table 126. Mexico Live Attenuated Vaccines, by Application USD Million (2018-2023)
  • Table 127. Mexico Live Attenuated Vaccines, by End Use USD Million (2018-2023)
  • Table 128. Mexico Live Attenuated Vaccines, by Vaccines USD Million (2018-2023)
  • Table 129. Live Attenuated Vaccines Sales: by Type(Unit)
  • Table 130. Live Attenuated Vaccines Sales Bacterial , by Region Unit (2018-2023)
  • Table 131. Live Attenuated Vaccines Sales Viral , by Region Unit (2018-2023)
  • Table 132. Live Attenuated Vaccines Sales: by Application(Unit)
  • Table 133. Live Attenuated Vaccines Sales Hospitals , by Region Unit (2018-2023)
  • Table 134. Live Attenuated Vaccines Sales Clinics , by Region Unit (2018-2023)
  • Table 135. Live Attenuated Vaccines Sales Research Institutes , by Region Unit (2018-2023)
  • Table 136. Live Attenuated Vaccines Sales Others , by Region Unit (2018-2023)
  • Table 137. Live Attenuated Vaccines Sales: by End Use(Unit)
  • Table 138. Live Attenuated Vaccines Sales Geriatrics , by Region Unit (2018-2023)
  • Table 139. Live Attenuated Vaccines Sales Adults , by Region Unit (2018-2023)
  • Table 140. Live Attenuated Vaccines Sales Adolescents , by Region Unit (2018-2023)
  • Table 141. Live Attenuated Vaccines Sales Child , by Region Unit (2018-2023)
  • Table 142. Live Attenuated Vaccines Sales: by Vaccines(Unit)
  • Table 143. Live Attenuated Vaccines Sales Measles, mumps, rubella (MMR combined vaccine) , by Region Unit (2018-2023)
  • Table 144. Live Attenuated Vaccines Sales Rotavirus , by Region Unit (2018-2023)
  • Table 145. Live Attenuated Vaccines Sales Smallpox , by Region Unit (2018-2023)
  • Table 146. Live Attenuated Vaccines Sales Chickenpox , by Region Unit (2018-2023)
  • Table 147. Live Attenuated Vaccines Sales Yellow fever , by Region Unit (2018-2023)
  • Table 148. South America Live Attenuated Vaccines Sales, by Country Unit (2018-2023)
  • Table 149. South America Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 150. South America Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 151. South America Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 152. South America Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 153. Brazil Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 154. Brazil Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 155. Brazil Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 156. Brazil Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 157. Argentina Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 158. Argentina Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 159. Argentina Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 160. Argentina Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 161. Rest of South America Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 162. Rest of South America Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 163. Rest of South America Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 164. Rest of South America Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 165. Asia Pacific Live Attenuated Vaccines Sales, by Country Unit (2018-2023)
  • Table 166. Asia Pacific Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 167. Asia Pacific Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 168. Asia Pacific Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 169. Asia Pacific Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 170. China Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 171. China Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 172. China Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 173. China Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 174. Japan Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 175. Japan Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 176. Japan Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 177. Japan Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 178. India Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 179. India Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 180. India Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 181. India Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 182. South Korea Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 183. South Korea Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 184. South Korea Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 185. South Korea Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 186. Taiwan Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 187. Taiwan Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 188. Taiwan Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 189. Taiwan Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 190. Australia Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 191. Australia Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 192. Australia Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 193. Australia Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 194. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 195. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 196. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 197. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 198. Europe Live Attenuated Vaccines Sales, by Country Unit (2018-2023)
  • Table 199. Europe Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 200. Europe Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 201. Europe Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 202. Europe Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 203. Germany Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 204. Germany Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 205. Germany Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 206. Germany Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 207. France Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 208. France Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 209. France Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 210. France Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 211. Italy Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 212. Italy Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 213. Italy Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 214. Italy Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 215. United Kingdom Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 216. United Kingdom Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 217. United Kingdom Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 218. United Kingdom Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 219. Netherlands Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 220. Netherlands Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 221. Netherlands Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 222. Netherlands Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 223. Rest of Europe Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 224. Rest of Europe Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 225. Rest of Europe Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 226. Rest of Europe Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 227. MEA Live Attenuated Vaccines Sales, by Country Unit (2018-2023)
  • Table 228. MEA Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 229. MEA Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 230. MEA Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 231. MEA Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 232. Middle East Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 233. Middle East Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 234. Middle East Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 235. Middle East Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 236. Africa Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 237. Africa Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 238. Africa Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 239. Africa Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 240. North America Live Attenuated Vaccines Sales, by Country Unit (2018-2023)
  • Table 241. North America Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 242. North America Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 243. North America Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 244. North America Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 245. United States Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 246. United States Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 247. United States Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 248. United States Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 249. Canada Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 250. Canada Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 251. Canada Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 252. Canada Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 253. Mexico Live Attenuated Vaccines Sales, by Type Unit (2018-2023)
  • Table 254. Mexico Live Attenuated Vaccines Sales, by Application Unit (2018-2023)
  • Table 255. Mexico Live Attenuated Vaccines Sales, by End Use Unit (2018-2023)
  • Table 256. Mexico Live Attenuated Vaccines Sales, by Vaccines Unit (2018-2023)
  • Table 257. Live Attenuated Vaccines: by Type(USD/Units)
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Live Attenuated Vaccines: by Type(USD Million)
  • Table 268. Live Attenuated Vaccines Bacterial , by Region USD Million (2025-2030)
  • Table 269. Live Attenuated Vaccines Viral , by Region USD Million (2025-2030)
  • Table 270. Live Attenuated Vaccines: by Application(USD Million)
  • Table 271. Live Attenuated Vaccines Hospitals , by Region USD Million (2025-2030)
  • Table 272. Live Attenuated Vaccines Clinics , by Region USD Million (2025-2030)
  • Table 273. Live Attenuated Vaccines Research Institutes , by Region USD Million (2025-2030)
  • Table 274. Live Attenuated Vaccines Others , by Region USD Million (2025-2030)
  • Table 275. Live Attenuated Vaccines: by End Use(USD Million)
  • Table 276. Live Attenuated Vaccines Geriatrics , by Region USD Million (2025-2030)
  • Table 277. Live Attenuated Vaccines Adults , by Region USD Million (2025-2030)
  • Table 278. Live Attenuated Vaccines Adolescents , by Region USD Million (2025-2030)
  • Table 279. Live Attenuated Vaccines Child , by Region USD Million (2025-2030)
  • Table 280. Live Attenuated Vaccines: by Vaccines(USD Million)
  • Table 281. Live Attenuated Vaccines Measles, mumps, rubella (MMR combined vaccine) , by Region USD Million (2025-2030)
  • Table 282. Live Attenuated Vaccines Rotavirus , by Region USD Million (2025-2030)
  • Table 283. Live Attenuated Vaccines Smallpox , by Region USD Million (2025-2030)
  • Table 284. Live Attenuated Vaccines Chickenpox , by Region USD Million (2025-2030)
  • Table 285. Live Attenuated Vaccines Yellow fever , by Region USD Million (2025-2030)
  • Table 286. South America Live Attenuated Vaccines, by Country USD Million (2025-2030)
  • Table 287. South America Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 288. South America Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 289. South America Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 290. South America Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 291. Brazil Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 292. Brazil Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 293. Brazil Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 294. Brazil Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 295. Argentina Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 296. Argentina Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 297. Argentina Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 298. Argentina Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 299. Rest of South America Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 300. Rest of South America Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 301. Rest of South America Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 302. Rest of South America Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 303. Asia Pacific Live Attenuated Vaccines, by Country USD Million (2025-2030)
  • Table 304. Asia Pacific Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 305. Asia Pacific Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 306. Asia Pacific Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 307. Asia Pacific Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 308. China Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 309. China Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 310. China Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 311. China Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 312. Japan Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 313. Japan Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 314. Japan Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 315. Japan Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 316. India Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 317. India Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 318. India Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 319. India Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 320. South Korea Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 321. South Korea Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 322. South Korea Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 323. South Korea Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 324. Taiwan Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 325. Taiwan Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 326. Taiwan Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 327. Taiwan Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 328. Australia Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 329. Australia Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 330. Australia Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 331. Australia Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 332. Rest of Asia-Pacific Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 333. Rest of Asia-Pacific Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 334. Rest of Asia-Pacific Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 335. Rest of Asia-Pacific Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 336. Europe Live Attenuated Vaccines, by Country USD Million (2025-2030)
  • Table 337. Europe Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 338. Europe Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 339. Europe Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 340. Europe Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 341. Germany Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 342. Germany Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 343. Germany Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 344. Germany Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 345. France Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 346. France Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 347. France Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 348. France Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 349. Italy Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 350. Italy Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 351. Italy Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 352. Italy Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 353. United Kingdom Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 354. United Kingdom Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 355. United Kingdom Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 356. United Kingdom Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 357. Netherlands Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 358. Netherlands Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 359. Netherlands Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 360. Netherlands Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 361. Rest of Europe Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 362. Rest of Europe Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 363. Rest of Europe Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 364. Rest of Europe Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 365. MEA Live Attenuated Vaccines, by Country USD Million (2025-2030)
  • Table 366. MEA Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 367. MEA Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 368. MEA Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 369. MEA Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 370. Middle East Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 371. Middle East Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 372. Middle East Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 373. Middle East Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 374. Africa Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 375. Africa Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 376. Africa Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 377. Africa Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 378. North America Live Attenuated Vaccines, by Country USD Million (2025-2030)
  • Table 379. North America Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 380. North America Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 381. North America Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 382. North America Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 383. United States Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 384. United States Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 385. United States Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 386. United States Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 387. Canada Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 388. Canada Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 389. Canada Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 390. Canada Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 391. Mexico Live Attenuated Vaccines, by Type USD Million (2025-2030)
  • Table 392. Mexico Live Attenuated Vaccines, by Application USD Million (2025-2030)
  • Table 393. Mexico Live Attenuated Vaccines, by End Use USD Million (2025-2030)
  • Table 394. Mexico Live Attenuated Vaccines, by Vaccines USD Million (2025-2030)
  • Table 395. Live Attenuated Vaccines Sales: by Type(Unit)
  • Table 396. Live Attenuated Vaccines Sales Bacterial , by Region Unit (2025-2030)
  • Table 397. Live Attenuated Vaccines Sales Viral , by Region Unit (2025-2030)
  • Table 398. Live Attenuated Vaccines Sales: by Application(Unit)
  • Table 399. Live Attenuated Vaccines Sales Hospitals , by Region Unit (2025-2030)
  • Table 400. Live Attenuated Vaccines Sales Clinics , by Region Unit (2025-2030)
  • Table 401. Live Attenuated Vaccines Sales Research Institutes , by Region Unit (2025-2030)
  • Table 402. Live Attenuated Vaccines Sales Others , by Region Unit (2025-2030)
  • Table 403. Live Attenuated Vaccines Sales: by End Use(Unit)
  • Table 404. Live Attenuated Vaccines Sales Geriatrics , by Region Unit (2025-2030)
  • Table 405. Live Attenuated Vaccines Sales Adults , by Region Unit (2025-2030)
  • Table 406. Live Attenuated Vaccines Sales Adolescents , by Region Unit (2025-2030)
  • Table 407. Live Attenuated Vaccines Sales Child , by Region Unit (2025-2030)
  • Table 408. Live Attenuated Vaccines Sales: by Vaccines(Unit)
  • Table 409. Live Attenuated Vaccines Sales Measles, mumps, rubella (MMR combined vaccine) , by Region Unit (2025-2030)
  • Table 410. Live Attenuated Vaccines Sales Rotavirus , by Region Unit (2025-2030)
  • Table 411. Live Attenuated Vaccines Sales Smallpox , by Region Unit (2025-2030)
  • Table 412. Live Attenuated Vaccines Sales Chickenpox , by Region Unit (2025-2030)
  • Table 413. Live Attenuated Vaccines Sales Yellow fever , by Region Unit (2025-2030)
  • Table 414. South America Live Attenuated Vaccines Sales, by Country Unit (2025-2030)
  • Table 415. South America Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 416. South America Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 417. South America Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 418. South America Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 419. Brazil Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 420. Brazil Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 421. Brazil Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 422. Brazil Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 423. Argentina Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 424. Argentina Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 425. Argentina Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 426. Argentina Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 427. Rest of South America Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 428. Rest of South America Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 429. Rest of South America Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 430. Rest of South America Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 431. Asia Pacific Live Attenuated Vaccines Sales, by Country Unit (2025-2030)
  • Table 432. Asia Pacific Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 433. Asia Pacific Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 434. Asia Pacific Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 435. Asia Pacific Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 436. China Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 437. China Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 438. China Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 439. China Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 440. Japan Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 441. Japan Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 442. Japan Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 443. Japan Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 444. India Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 445. India Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 446. India Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 447. India Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 448. South Korea Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 449. South Korea Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 450. South Korea Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 451. South Korea Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 452. Taiwan Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 453. Taiwan Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 454. Taiwan Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 455. Taiwan Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 456. Australia Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 457. Australia Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 458. Australia Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 459. Australia Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 460. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 461. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 462. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 463. Rest of Asia-Pacific Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 464. Europe Live Attenuated Vaccines Sales, by Country Unit (2025-2030)
  • Table 465. Europe Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 466. Europe Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 467. Europe Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 468. Europe Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 469. Germany Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 470. Germany Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 471. Germany Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 472. Germany Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 473. France Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 474. France Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 475. France Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 476. France Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 477. Italy Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 478. Italy Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 479. Italy Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 480. Italy Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 481. United Kingdom Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 482. United Kingdom Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 483. United Kingdom Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 484. United Kingdom Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 485. Netherlands Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 486. Netherlands Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 487. Netherlands Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 488. Netherlands Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 489. Rest of Europe Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 490. Rest of Europe Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 491. Rest of Europe Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 492. Rest of Europe Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 493. MEA Live Attenuated Vaccines Sales, by Country Unit (2025-2030)
  • Table 494. MEA Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 495. MEA Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 496. MEA Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 497. MEA Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 498. Middle East Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 499. Middle East Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 500. Middle East Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 501. Middle East Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 502. Africa Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 503. Africa Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 504. Africa Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 505. Africa Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 506. North America Live Attenuated Vaccines Sales, by Country Unit (2025-2030)
  • Table 507. North America Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 508. North America Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 509. North America Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 510. North America Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 511. United States Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 512. United States Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 513. United States Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 514. United States Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 515. Canada Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 516. Canada Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 517. Canada Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 518. Canada Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 519. Mexico Live Attenuated Vaccines Sales, by Type Unit (2025-2030)
  • Table 520. Mexico Live Attenuated Vaccines Sales, by Application Unit (2025-2030)
  • Table 521. Mexico Live Attenuated Vaccines Sales, by End Use Unit (2025-2030)
  • Table 522. Mexico Live Attenuated Vaccines Sales, by Vaccines Unit (2025-2030)
  • Table 523. Live Attenuated Vaccines: by Type(USD/Units)
  • Table 524. Research Programs/Design for This Report
  • Table 525. Key Data Information from Secondary Sources
  • Table 526. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Live Attenuated Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Live Attenuated Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Live Attenuated Vaccines: by End Use USD Million (2018-2023)
  • Figure 7. Global Live Attenuated Vaccines: by Vaccines USD Million (2018-2023)
  • Figure 8. South America Live Attenuated Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Live Attenuated Vaccines Share (%), by Country
  • Figure 10. Europe Live Attenuated Vaccines Share (%), by Country
  • Figure 11. MEA Live Attenuated Vaccines Share (%), by Country
  • Figure 12. North America Live Attenuated Vaccines Share (%), by Country
  • Figure 13. Global Live Attenuated Vaccines: by Type Unit (2018-2023)
  • Figure 14. Global Live Attenuated Vaccines: by Application Unit (2018-2023)
  • Figure 15. Global Live Attenuated Vaccines: by End Use Unit (2018-2023)
  • Figure 16. Global Live Attenuated Vaccines: by Vaccines Unit (2018-2023)
  • Figure 17. South America Live Attenuated Vaccines Share (%), by Country
  • Figure 18. Asia Pacific Live Attenuated Vaccines Share (%), by Country
  • Figure 19. Europe Live Attenuated Vaccines Share (%), by Country
  • Figure 20. MEA Live Attenuated Vaccines Share (%), by Country
  • Figure 21. North America Live Attenuated Vaccines Share (%), by Country
  • Figure 22. Global Live Attenuated Vaccines: by Type USD/Units (2018-2023)
  • Figure 23. Global Live Attenuated Vaccines share by Players 2023 (%)
  • Figure 24. Global Live Attenuated Vaccines share by Players (Top 3) 2023(%)
  • Figure 25. Global Live Attenuated Vaccines share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 31. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 37. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 39. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 40. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 41. Emergent BioSolution, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Emergent BioSolution, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. MedImmune, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 44. MedImmune, LLC (United States) Revenue: by Geography 2023
  • Figure 45. Global Live Attenuated Vaccines: by Type USD Million (2025-2030)
  • Figure 46. Global Live Attenuated Vaccines: by Application USD Million (2025-2030)
  • Figure 47. Global Live Attenuated Vaccines: by End Use USD Million (2025-2030)
  • Figure 48. Global Live Attenuated Vaccines: by Vaccines USD Million (2025-2030)
  • Figure 49. South America Live Attenuated Vaccines Share (%), by Country
  • Figure 50. Asia Pacific Live Attenuated Vaccines Share (%), by Country
  • Figure 51. Europe Live Attenuated Vaccines Share (%), by Country
  • Figure 52. MEA Live Attenuated Vaccines Share (%), by Country
  • Figure 53. North America Live Attenuated Vaccines Share (%), by Country
  • Figure 54. Global Live Attenuated Vaccines: by Type Unit (2025-2030)
  • Figure 55. Global Live Attenuated Vaccines: by Application Unit (2025-2030)
  • Figure 56. Global Live Attenuated Vaccines: by End Use Unit (2025-2030)
  • Figure 57. Global Live Attenuated Vaccines: by Vaccines Unit (2025-2030)
  • Figure 58. South America Live Attenuated Vaccines Share (%), by Country
  • Figure 59. Asia Pacific Live Attenuated Vaccines Share (%), by Country
  • Figure 60. Europe Live Attenuated Vaccines Share (%), by Country
  • Figure 61. MEA Live Attenuated Vaccines Share (%), by Country
  • Figure 62. North America Live Attenuated Vaccines Share (%), by Country
  • Figure 63. Global Live Attenuated Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline Plc. (United Kingdom)
  • Merck & Co. (United States)
  • Novartis International AG (Switzerland)
  • Pfizer, Inc. (United States)
  • Astellas Pharma Inc. (Japan)
  • Johnson & Johnson (United States)
  • CSL Limited (Australia)
  • Emergent BioSolution, Inc. (United States)
  • MedImmune, LLC (United States)
Additional players considered in the study are as follows:
Sanofi (France) , Serum Institute Of India Pvt. Ltd. (India)
Select User Access Type

Key Highlights of Report


Apr 2024 206 Pages 84 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Live Attenuated Vaccines Quantitative research analysis
Global Live Attenuated Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Live Attenuated Vaccines Market are by type [Bacterial and Viral], by end use application [Hospitals, Clinics, Research Institutes and Others].
The Live Attenuated Vaccines Market is gaining popularity and expected to see strong valuation by 2030.
  • Rising Awareness of Vaccination Worldwide
  • Increasing Government Initiative and Providing Fundings for Vaccine Programs

Know More About Global Live Attenuated Vaccines Report?

Have a Query? Click Here

Other Related Reports

Drug Excipients Comprehensive Study by Type (Organic Chemicals, Inorganic Chemicals, Others), Application (Solid Drugs, Semisolid Drugs, Liquid Drugs), Functionality (Disintegrants, Colorants, Lubric...
$ 3650
Cocoa Butter Comprehensive Study by Application (Food & Beverage Industry, Pharmaceuticals, Personal Care & Cosmetics), Category (Organic, Conventional, Deodorized), Form (Refined, Unrefined), End Us...
$ 3350
Drugs for Herpes Labialis Comprehensive Study by Type (Aciclovir, Valacyclovir, Famciclovir, Docosanol, Other), Route of Administration (External Use, Oral, Injection), Distribution Channel (Hospital...
$ 3450
Nicotine Gum Comprehensive Study by Type (Flavored {Mint, Fruit, Cinnamon, and Others}, Unflavored), Application (Hospitals, Withdrawal Clinics, Individual Smokers, Others), Sales Channel (Brick and ...
$ 3650
Medical Sevofluran Comprehensive Study by Type (Generic Drug, Original Drug), Patient type (Children, Adults), Concentrations (5% sevoflurane (Adults), 7% sevoflurane (children), Others) Players and ...
$ 3500
Herb Oil Comprehensive Study by Type (Basil, Mint, Thyme, Dill, Other Herbs, Market by Extraction Method, Distillation, Solvent Extraction, Cold Pressing, Others), Application (Personal Care and Cosm...
$ 3450